Opthea Limited (OPT)

Market Cap	499.24M
Revenue (ttm)	261,859
Net Income (ttm)	-220.24M
Shares Out	1.23B
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,663
Open	3.320
Previous Close	3.280
Day's Range	3.260 - 3.370
52-Week Range	1.790 - 5.450
Beta	1.54
Analysts	Strong Buy
Price Target	12.00 (+265.85%)
Earnings Date	Aug 30, 2024

About OPT

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit V...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: OPT
• Website: https://opthea.com

Financial Performance

In 2024, Opthea's revenue was $261,859, a decrease of -32.03% compared to the previous year's $385,275. Losses were -$220.24 million, 54.5% more than in 2023.

Analyst Forecast

According to one analyst, the rating for OPT stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(265.85% upside)

Analyst Consensus: Strong Buy